CoChat

Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy

Open access
Ferrara, Roberto, Naigeon, Marie, Auclin, Edouard, Duchemann, Boris, Cassard, Lydie, Jouniaux, Jean-Mehdi, Boselli, Lisa, Grivel, Jonathan, Desnoyer, Aude, Mezquita, Laura, Texier, Matthieu, Caramella, Caroline, Hendriks, Lizza, Planchard, David, Remon, Jordi, Sangaletti, Sabina, Proto, Claudia, Garassino, Marina C., Soria, Jean-Charles, Marabelle, Aurelien, Voisin, Anne-Laure, Farhane, Siham, Besse, Benjamin, Chaput, Nathalie · 2021 · Clinical Cancer Research
Cited by 163

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Purpose: CD28, CD57, and KLRG1 have been previously identified as markers of T-cell immunosenescence. The impact of immunosenescence on anti-PD(L)-1 (ICI) or platinum-based chemotherapy (PCT) in patients with advanced non–small cell lung cancer (aNSCLC) is unknown. Experimental Design: The percentage of CD28−, CD57+, KLRG1+ among CD8+ T cells [senescent immune phenotype (SIP)] was assessed by flow cytometry on blood from patients with aNSCLC before single-agent ICI (discovery cohort). A SIP cut-off was identified by log-rank maximization method and patients with aNSCLC treated with ICI (validation cohort) or PCT were classified accordingly. Proliferation and functional properties of SIP+ CD8+ T cells were assessed in vitro. Results: In the ICI discovery cohort (N = 37), SIP cut-off was 39.5%, 27% of patients were SIP+. In the ICI validation cohort (N = 46), SIP+ status was found in 28% of patients and significantly correlated with worse objective response rate (ORR; 0% vs. 30%, P = 0.04), median progression-free survival (PFS) [1.8 (95% confidence interval (CI), 1.3-NR) vs. 6.4 (95% CI, 2–19) months, P = 0.009] and median overall survival, OS [2.8 (95% CI, 2.0-NR) vs. 20.8 (95% CI, 6.0-NR) months, P = 0.02]. SIP+ status was significantly associated with circulating specific immunephenotypes, in vitro lower CD8+ T cells proliferation, lower IL2 and higher TNFα and IFNγ production. In the ICI-pooled population (N = 83), SIP+ status did not correlate with any clinical characteristics and it was associated with significantly worse ORR, PFS, and OS. In PCT cohort (N = 61), 11% of patients were SIP+. SIP status did not correlate with outcomes upon PCT. Conclusions: Circulating T-cell immunosenescence is observed in up to 28% of patients with aNSCLC and correlates with lack of benefit from ICI but not from PCT. See related commentary by Salas-Benito et al., p. 374

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-1420

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 163

Metadata

Authors
Ferrara, R., Naigeon, M., Auclin, E., Duchemann, B., Cassard, L., Jouniaux, J.-M., Boselli, L., Grivel, J., Desnoyer, A., Mezquita, L., Texier, M., Caramella, C., Hendriks, L., Planchard, D., Remon, J., Sangaletti, S., Proto, C., Garassino, M. C., Soria, J.-C., Marabelle, A., Voisin, A.-L., Farhane, S., Besse, B., & Chaput, N.
Venue
Clinical Cancer Research
Published
2021-01-15
Volume
27
Issue
2
Pages
492-503
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3083439485
Cited by
163
References
25
FWCI
6.18
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-1420
The paper
Ferrara, R., Naigeon, M., Auclin, E., Duchemann, B., Cassard, L., Jouniaux, J.-M., Boselli, L., Grivel, J., Desnoyer, A., Mezquita, L., Texier, M., Caramella, C., Hendriks, L., Planchard, D., Remon, J., Sangaletti, S., Proto, C., Garassino, M. C., Soria, J.-C., . . . Chaput, N. (2021). Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-1420

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.